Results 181 to 190 of about 23,522 (211)

Mechanism and modification of rejection of heterografts between divergent species. [PDF]

, 1970
Amemiya, H, Boehmig, HJ, Coburg, AJ, Dixon, FJ, Giles, GR, Hathaway, WE, Lilly, J, Starzl, TE, Takagi, H, Wilson, CB   +9 more
core  

A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4

Advanced Science, EarlyView.
This work identifies CD3.NKp46.CD19.NK1.1. NK‐B cells enriched in PDK1‐deficient yet present in wild‐type bone marrow. IL‐15 (via CD122) and TLR9‐microbiota signaling maintain their E4BP4 expression. These cells demonstrate innate immunity, preferentially differentiate into B cells, and unveil a novel microbiota‐ and IL‐15‐dependent regulatory pathway ...
Junming He, Xinlei Hou, Xiaomei Feng, Yayun Dong, Mengqi Ren, Surong Deng, Xinru Yang, Donglin Chen, Lingna Zhao, Shasha Chen, Meixiang Yang, Zhongjun Dong   +11 more
wiley   +1 more source

CD16A Shedding Regulates Innate Cell Engager-Induced Serial Killing by Natural Killer Cells. [PDF]

Eur J Immunol
Zambarda C, Guldevall K, Breunig C, Toullec D, Sandoz PA, Carannante V, Xu S, Ross P, Kuhnigk K, Sandström N, Fontana J, Wingert S, Pinto S, Knoch J, Hussain A, Wagner AK, Pahl J, Alici E, Koch J, Önfelt B.   +19 more
europepmc   +1 more source

NAD+‐Dependent Enzyme SIRT3 Limits Intestinal Epithelial Cell Functions Through NAD+ Synthesis Pathway in Colorectal Cancer

Advanced Science, EarlyView.
Microbiota‐derived quinolinic acid is used as an alternative source of replenishing the intracellular NAD+ pool induced by SIRT3 deficiency to regulate intestinal epithelial cell and T cell function, which has implications for targeting intestinal epithelial cells as an approach to the treatment of immune‐associated diseases, including colorectal ...
Ruiying Niu, Yingjie Dong, Jianghui Tong, Jingxuan Xia, Longhao Zhao, Zi Geng, Yingxin Lin, Jinghe Zhang, Xinyi Liu, Manqi Fang, Xi Jin, Yujing Bi, Guangwei Liu   +12 more
wiley   +1 more source

Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects. [PDF]

Pharmaceuticals (Basel)
Jacob S, Varkey NR, Boddu SHS, Gorain B, Rao R, Nair AB.   +5 more
europepmc   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

Advanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu   +4 more
wiley   +1 more source

Long-term Graft and Patient Survival in Kidney Transplant Recipients With High Levels of Preformed DSAs (MFI > 3000): A Propensity Score-matched Analysis. [PDF]

Transplant Direct
Debiais-Deschamps C, Amrouche L, Rabant M, Duong Van Huyen JP, Burger C, Roger C, Le Stang MB, Troger A, Leon J, Martinez F, Sberro-Soussan R, Scemla A, Peraldi MN, Zuber J, Anglicheau D, Legendre C, Aubert O.   +16 more
europepmc   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Serum Sickness-Like Reaction: A Narrative Review of Epidemiology, Immunopathogenesis, Diagnostic Challenges, and Therapeutic Approaches. [PDF]

Clin Pract
Chatzigrigoriadis C, Koufopoulos E, Avramidis P, Erginousakis I, Karakoida V, Papadopoulos T, Sperdouli D, Tachliabouri ME, Vilanakis K, Zampounidis D, Michou V, Eskitzis P, Galiatsatos P, Lavasidis L, Anestakis D.   +14 more
europepmc   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source